Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 7/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | TDO2 | P48775 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28667424 | 0.86 | MAPT (0.50) | MAPTNPC1KMT2ARAB9AHTT | |
| SCHEMBL25208513 | 0.85 | CES2 (0.53) | MAPTNPC1KMT2ARAB9AHTT | |
| SCHEMBL31582781 | 0.82 | F2R (0.44) | MAPTNPC1KMT2ARAB9AHTT | |
| SCHEMBL25204030 | 0.81 | CES2 (0.53) | MAPTNPC1KMT2ARAB9AHTT | |
| SCHEMBL109588 | 0.79 | CA12 (0.67) | MAPTNPC1KMT2ARAB9ALMNA | |
| SCHEMBL1479361 | 0.79 | HSP90AB1 (0.67) | MAPTNPC1KMT2ARAB9AHTT | |
| SCHEMBL29368949 | 0.79 | HSP90AB1 (0.67) | MAPTNPC1KMT2ARAB9AHTT | |
| SCHEMBL485869 | 0.79 | F2R (0.44) | MAPTNPC1KMT2ARAB9AHTT | |
| SCHEMBL14186623 | 0.76 | GAA (0.46) | MAPTKMT2AHTTLMNASMN1; SMN2 | |
| SCHEMBL1701610 | 0.75 | PTPN1 (0.52) | MAPTNPC1KMT2ARAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326634-B1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140235672-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-08-21 | — | — | US | disclosed |
| US-8759390-B2 | Chromene modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| CN-102159562-A | Chromene modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO | 2011-08-17 | — | — | CN | disclosed |
| EP-2326634-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110112146-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-12 | — | — | US | disclosed |
| WO-2010009069-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235672-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR3, CCR2 | MAPT 4816/4885NPC1 2911/4885KMT2A 4045/4885 |
| US-20110112146-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR3, CCR2 | MAPT 4827/4885NPC1 2878/4885KMT2A 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.